We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Does the oncology community have a rejection bias when it comes to repurposed drugs?
- Authors
Gyawali, Bishal; Pantziarka, Pan; Crispino, Sergio; Bouche, Gauthier
- Abstract
Among the various measures proposed to combat the challenge of financial toxicity in cancer care, an important strategy is the use of lower-priced drugs instead of expensive alternatives. However, the oncology community seems to either ignore or more readily reject cheaper drugs in cancer care compared to more expensive alternatives. In this commentary, we present three examples of lower-priced drugs rejected or ignored by the oncology community and contrast this with three expensive drugs where persistent optimism remained despite negative clinical trial results. We argue that all drugs be held to the same rigorous standards - this not only includes skepticism in the absence of sound evidence, but also the suspension of premature judgement as has happened in the cases of repurposed drugs.
- Subjects
DRUG efficacy; ONCOLOGY; RANDOMIZED controlled trials
- Publication
Ecancermedicalscience, 2018, Vol 12, Issue 792-818, p1
- ISSN
1754-6605
- Publication type
Article
- DOI
10.3332/ecancer.2018.ed76